Public-domain · open source
OpenJurist
← 630 F.3d 546 - Bausch v. Stryker Corp.

Bausch v. Stryker Corp.’s Empirical Analysis

630 F.3d 546 · 2010

Citation profile

128
cited by 128 later decisions
1
cited 1 times by the Supreme Court
7
states following
October 2024
most recently cited

26 federal appellate · 12 district · 8 state decisions

Appellate journey

Relationships

Applies 21 U.S.C. § 351 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 360C (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 360E (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 360K (Federal Food, Drug, and Cosmetic Act)

Relies on Bell Atlantic Corp. v. Twombly · Ashcroft v. Iqbal · Foman v. Davis · Swierkiewicz v. Sorema N. A. · Rice v. Santa Fe Elevator Corp.

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 128 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “[Emphasis supplied.] Defendants' proposed distinction between concrete, product-specific requirements and more general requirements would also leave injured patients without any remedy for a wide range of harmful violations of federal law. The FDA regulations contain many requirements that are not concrete or product-specific, yet which are obviously vital to producing safe and effective medical devices. For example, the regulations require each manufacturer to”
    5 later decisions quote this exact passage · from the dissent
  2. “[t]he idea that Congress would have granted civil immunity to medical device manufacturers for their violations of federal law that hurt patients is, to say the least, counter-intuitive.” Bausch, 630 F.3d at 549 ; see also Hornbeck v. Medtronic, Inc., No. 13-C-7816, 2014 WL 2510817 , at (N.D.Ill. June 2, 2014) (noting that”
    3 later decisions quote this exact passage · from the majority
  3. “First, the meaning of the FDA's requirements will present questions of law for the court to decide, not questions of fact for a jury to decide. Second, those questions of law will be questions of federal law, subject to the usual processes for reconciling conflicting views.”
    3 later decisions quote this exact passage · from the dissent

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.